Diabetes Optimization in Total Joint Arthroplasty: Perioperative Markers, Pharmacologic Strategies, and Wound Care Best Practices
Adopting dynamic biomarker panels, prioritizing GLP-1-based regimens, and applying targeted incision management can meaningfully curb diabetes-related complications after arthroplasty. Prospective trials should refine biomarker cutoffs, weigh SGLT-2 risks against transfusion benefits, and define cost-effective wound care pathways.
Authors
- Fong H. Nham (ORCID: https://orcid.org/0000-0002-6028-846X)
- Usher Khan (ORCID: https://orcid.org/0009-0006-9804-7393)
- Zachary Crespi
- Mouhanad El Othmani
Institutions
- Fordham University (US)
- Detroit Medical Center (US)
- Khan Academy (US)
- Optimization Technology (United States) (US)
Publication Details
- Journal
- JAAOS Global Research and Reviews
- Published
- 2026-02-01
- DOI
- https://doi.org/10.5435/jaaosglobal-d-25-00214
- Primary Topic
- Total Knee Arthroplasty Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00